A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies

BACKGROUND: Sunitinib treatment results in a compensatory increase in plasma VEGF levels. Acute withdrawal of sunitinib results in a proliferative withdrawal flare, primarily due to elevated VEGF levels. Concurrent sunitinib plus bevacizumab is poorly tolerated with high (37 %) incidence of microang...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Bruce, Justine Yang, Kolesar, Jill M., Hammers, Hans, Stein, Mark N., Carmichael, Lakeesha, Eickhoff, Jens, Johnston, Susan A., Binger, Kimberly A., Heideman, Jennifer L., Perlman, Scott B., Jeraj, Robert, Liu, Glenn
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2014
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4200479/
https://ncbi.nlm.nih.gov/pubmed/24414551
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-013-2373-9
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items